BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

490 related articles for article (PubMed ID: 24944472)

  • 1. Bedside ultrasound in the diagnosis of nonalcoholic fatty liver disease.
    Khov N; Sharma A; Riley TR
    World J Gastroenterol; 2014 Jun; 20(22):6821-5. PubMed ID: 24944472
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Radiologic evaluation of nonalcoholic fatty liver disease.
    Lee SS; Park SH
    World J Gastroenterol; 2014 Jun; 20(23):7392-402. PubMed ID: 24966609
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Diagnostic Performance of FibroTouch Ultrasound Attenuation Parameter and Liver Stiffness Measurement in Assessing Hepatic Steatosis and Fibrosis in Patients With Nonalcoholic Fatty Liver Disease.
    Qu Y; Song YY; Chen CW; Fu QC; Shi JP; Xu Y; Xie Q; Yang YF; Zhou YJ; Li LP; Xu MY; Cai XB; Zhang QD; Yu H; Fan JG; Lu LG
    Clin Transl Gastroenterol; 2021 Apr; 12(4):e00323. PubMed ID: 33848277
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hepatic artery resistive index (HARI) and non-alcoholic fatty liver disease (NAFLD) fibrosis score in NAFLD patients: cut-off suggestive of non-alcoholic steatohepatitis (NASH) evolution.
    Tana C; Tana M; Rossi S; Silingardi M; Schiavone C
    J Ultrasound; 2016 Sep; 19(3):183-9. PubMed ID: 27635163
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ultrasonographic Nonalcoholic Fatty Pancreas Is Associated with Advanced Fibrosis in NAFLD: A Retrospective Analysis.
    Rosenblatt R; Mehta A; Snell D; Hissong E; Kierans AS; Kumar S
    Dig Dis Sci; 2019 Jan; 64(1):262-268. PubMed ID: 30269271
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum cytokeratin-18 and its relation to liver fibrosis and steatosis diagnosed by FibroScan and controlled attenuation parameter in nonalcoholic fatty liver disease and hepatitis C virus patients.
    Darweesh SK; AbdElAziz RA; Abd-ElFatah DS; AbdElazim NA; Fathi SA; Attia D; AbdAllah M
    Eur J Gastroenterol Hepatol; 2019 May; 31(5):633-641. PubMed ID: 30839434
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multiparametric magnetic resonance imaging for the assessment of non-alcoholic fatty liver disease severity.
    Pavlides M; Banerjee R; Tunnicliffe EM; Kelly C; Collier J; Wang LM; Fleming KA; Cobbold JF; Robson MD; Neubauer S; Barnes E
    Liver Int; 2017 Jul; 37(7):1065-1073. PubMed ID: 27778429
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biopsy and Noninvasive Methods to Assess Progression of Nonalcoholic Fatty Liver Disease.
    Bedossa P; Patel K
    Gastroenterology; 2016 Jun; 150(8):1811-1822.e4. PubMed ID: 27003601
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Current and Emerging Biomarkers and Imaging Modalities for Nonalcoholic Fatty Liver Disease: Clinical and Research Applications.
    Hydes T; Brown E; Hamid A; Bateman AC; Cuthbertson DJ
    Clin Ther; 2021 Sep; 43(9):1505-1522. PubMed ID: 34400007
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MR elastography is effective for the non-invasive evaluation of fibrosis and necroinflammatory activity in patients with nonalcoholic fatty liver disease.
    Costa-Silva L; Ferolla SM; Lima AS; Vidigal PVT; Ferrari TCA
    Eur J Radiol; 2018 Jan; 98():82-89. PubMed ID: 29279175
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of liver biopsy in nonalcoholic fatty liver disease.
    Nalbantoglu IL; Brunt EM
    World J Gastroenterol; 2014 Jul; 20(27):9026-37. PubMed ID: 25083076
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Noninvasive Assessment of Liver Disease in Patients With Nonalcoholic Fatty Liver Disease.
    Castera L; Friedrich-Rust M; Loomba R
    Gastroenterology; 2019 Apr; 156(5):1264-1281.e4. PubMed ID: 30660725
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Accuracy of FibroScan Controlled Attenuation Parameter and Liver Stiffness Measurement in Assessing Steatosis and Fibrosis in Patients With Nonalcoholic Fatty Liver Disease.
    Eddowes PJ; Sasso M; Allison M; Tsochatzis E; Anstee QM; Sheridan D; Guha IN; Cobbold JF; Deeks JJ; Paradis V; Bedossa P; Newsome PN
    Gastroenterology; 2019 May; 156(6):1717-1730. PubMed ID: 30689971
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Magnetic Resonance Imaging More Accurately Classifies Steatosis and Fibrosis in Patients With Nonalcoholic Fatty Liver Disease Than Transient Elastography.
    Imajo K; Kessoku T; Honda Y; Tomeno W; Ogawa Y; Mawatari H; Fujita K; Yoneda M; Taguri M; Hyogo H; Sumida Y; Ono M; Eguchi Y; Inoue T; Yamanaka T; Wada K; Saito S; Nakajima A
    Gastroenterology; 2016 Mar; 150(3):626-637.e7. PubMed ID: 26677985
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diagnosis of Non-alcoholic Fatty Liver Disease (NAFLD): Current Concepts.
    Papatheodoridi M; Cholongitas E
    Curr Pharm Des; 2018; 24(38):4574-4586. PubMed ID: 30652642
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Diagnostic modalities for nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, and associated fibrosis.
    Younossi ZM; Loomba R; Anstee QM; Rinella ME; Bugianesi E; Marchesini G; Neuschwander-Tetri BA; Serfaty L; Negro F; Caldwell SH; Ratziu V; Corey KE; Friedman SL; Abdelmalek MF; Harrison SA; Sanyal AJ; Lavine JE; Mathurin P; Charlton MR; Goodman ZD; Chalasani NP; Kowdley KV; George J; Lindor K
    Hepatology; 2018 Jul; 68(1):349-360. PubMed ID: 29222917
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diagnostic Performance of Quantitative Ultrasound Parameters in Non-alcoholic Fatty Liver Disease.
    Torkzaban M; Wessner CE; Halegoua-DeMarzio D; Lyshchik A; Nam K
    Acad Radiol; 2024 Jan; 31(1):199-211. PubMed ID: 37507328
    [TBL] [Abstract][Full Text] [Related]  

  • 18. How to Diagnose Nonalcoholic Fatty Liver Disease.
    de Alwis NM; Anstee QM; Day CP
    Dig Dis; 2016; 34 Suppl 1():19-26. PubMed ID: 27547937
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Accuracy of ultrasonographic fatty liver index using point-of-care ultrasound in stratifying non-alcoholic fatty liver disease patients.
    Sourianarayanane A; McCullough AJ
    Eur J Gastroenterol Hepatol; 2023 Jun; 35(6):654-661. PubMed ID: 37115988
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Contrast-enhanced ultrasonography could be a non-invasive method for differentiating none or mild from severe fibrosis in patients with biopsy proven non-alcoholic fatty liver disease.
    Nasr P; Hilliges A; Thorelius L; Kechagias S; Ekstedt M
    Scand J Gastroenterol; 2016 Sep; 51(9):1126-32. PubMed ID: 27161854
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.